TM9SF1 Inhibitors
TM9SF1 inhibitors encompass a diverse range of chemical compounds that attenuate the protein's functional activity through various biochemical and cellular mechanisms. These inhibitors can target the lysosomal environment, where TM9SF1 is localized, by altering the organelle's pH, ion homeostasis, or enzymatic activity. For instance, agents that elevate lysosomal pH prevent the necessary acidic conditions required for TM9SF1's optimal activity. Similarly, chemicals that hinder the acidification process or disrupt the proteolytic environment within lysosomes can indirectly impair TM9SF1's function. Moreover, compounds that interfere with the trafficking and localization of TM9SF1 also serve as indirect inhibitors. By blocking endocytosis or disrupting cytoskeletal elements crucial for vesicular transport, these inhibitors can trap TM9SF1 at the plasma membrane or elsewhere in the cell, preventing it from reaching or operating within the lysosomes.
Additionally, TM9SF1's activity can be modulated by the protein's interaction with membrane lipids. Chemicals that deplete cholesterol or perturb lipid homeostasis can influence TM9SF1 by altering the membrane microdomains it associates with, thereby affecting its function. Inhibitors that interfere with post-translational modifications such as phosphorylation or glycosylation can also lead to the functional inhibition of TM9SF1. If the protein's activity is regulated by such modifications, agents that prevent these biochemical processes can induce misfolding or instability of TM9SF1. Lastly, inhibitors of ATPases, which may be required for TM9SF1's maturation, trafficking, or degradation, can indirectly contribute to its inhibition by impairing the functions of these enzymes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Accumulates in lysosomes and raises their pH, affecting lysosomal enzymes' activity. As TM9SF1 is a lysosomal protein, the increased pH could impair its function by altering the lysosomal environment essential for its proper activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase) that prevents acidification of intracellular organelles such as lysosomes. Inhibition of acidification can impede TM9SF1 function, given its localization to lysosomal membranes which rely on acidic pH for proper function. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
An irreversible cysteine protease inhibitor that prevents the degradation of proteins within lysosomes. By inhibiting these proteases, E-64 may indirectly inhibit TM9SF1 by disrupting normal lysosomal processing and function. | ||||||
Methyl-β-cyclodextrin | 128446-36-6 | sc-215379A sc-215379 sc-215379C sc-215379B | 100 mg 1 g 10 g 5 g | $20.00 $48.00 $160.00 $82.00 | 19 | |
A cholesterol-depleting agent that disrupts lipid rafts within cellular membranes. Since TM9SF1 may be associated with membrane microdomains rich in cholesterol, its function could be inhibited by altering the lipid environment of the membrane. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A GTPase inhibitor that blocks dynamin-dependent endocytosis. As TM9SF1 could be involved in endocytic pathways, the inhibition of dynamin may indirectly affect the recycling and function of TM9SF1 by trapping it at the plasma membrane and preventing its normal trafficking to lysosomes. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
An actin polymerization inhibitor that can disrupt cytoskeletal dynamics. By disrupting the actin cytoskeleton, it may affect the trafficking and localization of TM9SF1, as the cytoskeleton is crucial for the transport of vesicles and proteins to lysosomes. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
An agent that causes intracellular cholesterol accumulation and disrupts the traffic of cholesterol and other lipids. As TM9SF1 is a protein potentially involved in lipid-related processes within lysosomes, U 18666A may lead to its functional inhibition by perturbing lipid homeostasis and transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
A sodium ionophore that disrupts lysosomal ion homeostasis. Since TM9SF1 function is likely dependent on the lysosomal environment, the disruption of ion gradients by this compound could inhibit the protein's activity by altering the lysosomal milieu. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule depolymerizing agent that disrupts microtubule dynamics, potentially affecting vesicular transport and organelle positioning. Given TM9SF1's potential role in vesicular transport to lysosomes, nocodazole may indirectly inhibit its function by interfering with its trafficking. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
A tyrosine kinase inhibitor that can interfere with several signaling pathways, potentially affecting the phosphorylation state and activity of proteins. If TM9SF1 is modulated by phosphorylation, genistein could indirectly inhibit its function by preventing this post-translational modification. | ||||||